Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study evaluates the effect of BRCA1&2 mutations on cardiovascular diseases by to comparing the endothelial function of male BRCA mutation carriers with that of age matched non-BRCA mutation carriers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| male BRCA mutations carriers | Other | Endothelial function assessment and Cardiovascular biomarkers |
|
| healthy males - control group | Other | Endothelial function assessment and Cardiovascular biomarkers |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Endothelial function assessment | Other | reactive hyperemia index |
|
| Measure | Description | Time Frame |
|---|---|---|
| reactive hyperemia index will be assessed using the Endo-PAT2000 | will be assessed using the Endo-PAT2000 | at baseline |
| Measure | Description | Time Frame |
|---|---|---|
| The level of high sensitivity troponin (hsTn) - a cardiovascular risk biomarker will be measured | high sensitivity troponin (hsTn) | at baseline |
| The level of C-reactive protein - a cardiovascular risk biomarker will be measured |
Not provided
Inclusion Criteria:
Exclusion Criteria:
History of, or current, malignancy
History of:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| David Margel, MD, PhD | Contact | +972(0)39376553 | sdmargel@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| David Margel, MD, PhD | Rabn Medical Center, Beilinson Campus | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rabin Medical Center, Beilinson Hospital | Recruiting | Petah Tikva | Israel |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Cardiovascular biomarkers | Other | Cardiovascular biomarkers will be measure to test other aspects of endothelial and cardiac function: high-sensitivity troponin (hsTn) , C-reactive protein , D-dimer, N-terminal pro-brain natriuretic peptide (NT-proBNP) |
|
| Endothelial cells | Other | Endothelial Progenitor Cells and Circulating Endothelial Cells profiles- will be characterized to evaluate endothelial injury. |
|
C-reactive protein
| at baseline |
| The level of D-dimer - a cardiovascular risk biomarker will be measured | D-dimer | at baseline |
| The level of N-terminal pro-brain natriuretic peptide (NT-proBNP) - a cardiovascular risk biomarker will be measured | N-terminal pro-brain natriuretic peptide (NT-proBNP) | at baseline |
| Endothelial Progenitor Cells profile (EPC) - will be characterized to evaluate endothelial injury. | Endothelial Progenitor Cells (EPC) | at baseline |
| Circulating Endothelial Cells profile (CEC) - will be characterized to evaluate endothelial injury. | Circulating Endothelial Cells (CEC) | at baseline |